Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Indolent Non-Hodgkin's Lymphoma
Conditions
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Trial Timeline
Mar 1, 2012 โ Jun 1, 2013
NCT ID
NCT01500083About Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2
Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2 is a phase 3 stage product being developed by Lundbeck for Indolent Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01500083. Target conditions include Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01500083 | Phase 3 | Completed |
Competing Products
15 competing products in Indolent Non-Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Linperlisib ๏ผ Rituximab | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| GP2013 | Novartis | Phase 1 | 33 |
| Ibrutinib + GA 101 | Roche | Phase 2 | 52 |
| Obinutuzumab + Bendamustine | Roche | Phase 2 | 52 |
| Placebo + Rituximab + Idelalisib | Gilead Sciences | Phase 3 | 76 |
| Idelalisib | Gilead Sciences | Phase 1/2 | 40 |
| Idelalisib + Rituximab + Bendamustine + Placebo | Gilead Sciences | Phase 3 | 76 |
| Idelalisib + Rituximab + Bendamustine + Ofatumumab + Fludarabine + Everolimus + Bortezomib + Chlorambucil + Lenalidomide | Gilead Sciences | Phase 1 | 32 |
| IBI376 | Innovent Biologics | Phase 2 | 51 |
| Copanlisib + Nivolumab + Rituximab | Bristol Myers Squibb | Phase 1 | 32 |
| SAR245409 | Sanofi | Phase 1 | 32 |
| Copanlisib (BAY80-6946) | Bayer | Pre-clinical | 20 |
| Bezuclastinib | Cogent Biosciences | Pre-clinical | 20 |